The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS
Primary Purpose
Post Partum Hemorrhage
Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
cesarean section
Misoprostol
Oxytocin
Sponsored by
About this trial
This is an interventional prevention trial for Post Partum Hemorrhage
Eligibility Criteria
Inclusion Criteria:
women attending for elective CS.
- Age between 20-35 years.
- Normal placental site
- Normal coagulation profile
- Full term pregnancies(above 37 wks)
- Medically free
- Spinal anesthesia
- Living baby
- Average liquor by U/S
Exclusion Criteria:
• Women attending for emergency CS
- .age below 20 or above 35
- Abnormal placentation (Placenta previa,accrete,increta or percreta)
- Women with coagulopathy
- Preterm pregnancies (before 37 wks)
- Medical disorder (Hypertension,Diabetes, Endocrinal disorder)
- General anathesia
- IUFD
- Oligo or polyhydraminos by U/S
Sites / Locations
- Kasr Alainy medical school
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Routine ecbolic group
Misoprostol group
Arm Description
100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
Outcomes
Primary Outcome Measures
postpartum hemorrhage
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03680339
Brief Title
The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS
Official Title
The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
September 2, 2018 (Actual)
Primary Completion Date
January 1, 2019 (Actual)
Study Completion Date
January 28, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
• Patients will be divided into two groups 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
Then we will compare between two groups regarding
Intaoperative blood loss
Risk of Postpartum hemorraghe in the first 24 hrs
HB pre and postoperative for all patients
Intraoperative blood loss will be estimated by the number and weight of soaked towels and amount of blood in suction unit
Detailed Description
• Patients will be divided into two groups 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
Then we will compare between two groups regarding
Intaoperative blood loss
Risk of Postpartum hemorraghe in the first 24 hrs
HB pre and postoperative for all patients
Intraoperative blood loss will be estimated by the number and weight of soaked towels and amount of blood in suction unit
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Partum Hemorrhage
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Routine ecbolic group
Arm Type
Active Comparator
Arm Description
100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
Arm Title
Misoprostol group
Arm Type
Active Comparator
Arm Description
The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
Intervention Type
Procedure
Intervention Name(s)
cesarean section
Intervention Description
CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Other Intervention Name(s)
Cytotec
Intervention Description
The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
Intervention Type
Drug
Intervention Name(s)
Oxytocin
Intervention Description
10 IU of oxytocin with fetal delivery
Primary Outcome Measure Information:
Title
postpartum hemorrhage
Time Frame
24 hours after cesarean section
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
women attending for elective CS.
Age between 20-35 years.
Normal placental site
Normal coagulation profile
Full term pregnancies(above 37 wks)
Medically free
Spinal anesthesia
Living baby
Average liquor by U/S
Exclusion Criteria:
• Women attending for emergency CS
.age below 20 or above 35
Abnormal placentation (Placenta previa,accrete,increta or percreta)
Women with coagulopathy
Preterm pregnancies (before 37 wks)
Medical disorder (Hypertension,Diabetes, Endocrinal disorder)
General anathesia
IUFD
Oligo or polyhydraminos by U/S
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmed maged, MD
Organizational Affiliation
Professor
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kasr Alainy medical school
City
Cairo
ZIP/Postal Code
12111
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31304593
Citation
Maged AM, Fawzi T, Shalaby MA, Samy A, Rabee MA, Ali AS, Hussein EA, Hammad B, Deeb WS. A randomized controlled trial of the safety and efficacy of preoperative rectal misoprostol for prevention of intraoperative and postoperative blood loss at elective cesarean delivery. Int J Gynaecol Obstet. 2019 Oct;147(1):102-107. doi: 10.1002/ijgo.12922. Epub 2019 Jul 25.
Results Reference
derived
Learn more about this trial
The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS
We'll reach out to this number within 24 hrs